Ionis EVP acquires 256 shares via employee plan

Ionis Pharmaceuticals EVP Research Eric Swayze reported an employee stock purchase plan transaction in Ionis common stock.

Accepted by SEC EDGAR 03/03/2026 - 05:29 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ionis Pharmaceuticals EVP Research Eric Swayze reported an employee stock purchase plan transaction in Ionis common stock. On February 27, 2026, he acquired 256 shares under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan at an average price of $48.8665 per share. These plan shares may not be sold until August 27, 2026. After this transaction, he directly held 32,361 common shares. A separate line also shows 318 shares held indirectly by his son.

Insider Trade Summary

Other: 256 shares

Other 1 txn

Insider Swayze Eric

Role EVP Research

Type	Security	Shares	Price	Value
Other	Common Stock	256	$48.8665	$13K
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 32,361 shares (Direct); Common Stock — 318 shares (Indirect, by Son)

Footnotes (1)

F1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026. These shares may not be sold until August 27, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ionis (IONS) report for Eric Swayze?

Eric Swayze reported acquiring 256 Ionis common shares through the company’s employee stock purchase plan. The transaction occurred on February 27, 2026, and reflects participation in a structured benefit program rather than an open-market trade.

At what price were Eric Swayze’s Ionis (IONS) ESPP shares acquired?

The 256 Ionis shares were acquired at an average price of $48.8665 per share. This price reflects the execution under the Amended and Restated 2000 Employee Stock Purchase Plan as of February 27, 2026.

How many Ionis (IONS) shares does Eric Swayze hold after this Form 4?

After the reported transaction, Eric Swayze directly held 32,361 Ionis common shares. The filing also shows an additional 318 shares held indirectly, attributed to his son, as a separate ownership line.

Are Eric Swayze’s newly acquired Ionis (IONS) ESPP shares immediately saleable?

No. The Form 4 states that the shares purchased under the employee stock purchase plan on February 27, 2026, may not be sold until August 27, 2026, creating a defined holding period for this batch.

What does the indirect ownership entry mean in the Ionis (IONS) Form 4?

The filing lists 318 Ionis common shares as held indirectly "by Son." This indicates a separate indirect ownership position related to Eric Swayze, distinct from his 32,361 directly held shares after the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swayze Eric

(Last)

(First)

(Middle)

2855 GAZELLE COURT

(Street)

CARLSBAD

92010

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP Research

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/27/2026		J		256⁽¹⁾	A	$48.8665	32,361	D
Common Stock								318	I	by Son

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026. These shares may not be sold until August 27, 2026.

	By: Patrick R. O'Neil, attorney-in-fact For: Eric Swayze	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR